Arkansas SB 387: TO AUTHORIZE OFF-LABEL USE OF DRUG TREATMENTS TO TREAT MEDICAID BENEFICIARIES WITH PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION.

Status: Notification that SB387 is now Act 637 (as of 2021-04-13)

State: Arkansas · Session: 2021 · Bill: SB 387

Sponsors: K. Hammer, Warren, Cloud, Irvin

View Arkansas SB 387 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.